Genentech, a member of the Roche Group, announced that phase III IMpassion130 study met its co-primary endpoint of progression free survival.
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.
